Bio-Rad Laboratories (BIO) Competitors

$287.49 +6.44 (+2.29%)

Closing price 05/20/2026 03:59 PM Eastern

Extended Trading

$287.86 +0.37 (+0.13%)

As of 04:06 AM Eastern

BIO vs. RGEN, TECH, A, AMN, and BIO.B

Should you buy Bio-Rad Laboratories stock or one of its competitors? MarketBeat compares Bio-Rad Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Rad Laboratories include Repligen (RGEN), Bio-Techne (TECH), Agilent Technologies (A), AMN Healthcare Services (AMN), and Bio-Rad Laboratories (BIO.B). These companies are all part of the "medical" sector.

How does Bio-Rad Laboratories compare to Repligen?

Repligen (NASDAQ:RGEN) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Repligen has a net margin of 6.73% compared to Bio-Rad Laboratories' net margin of 6.52%. Repligen's return on equity of 4.88% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
Bio-Rad Laboratories	6.52%	3.56%	2.49%

97.6% of Repligen shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Repligen has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Repligen presently has a consensus price target of $166.15, suggesting a potential upside of 48.70%. Bio-Rad Laboratories has a consensus price target of $303.33, suggesting a potential upside of 5.51%. Given Repligen's stronger consensus rating and higher probable upside, equities analysts plainly believe Repligen is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	8.54	$48.89M	$0.90	124.16
Bio-Rad Laboratories	$2.58B	2.98	$759.90M	$6.07	47.36

In the previous week, Repligen had 2 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 9 mentions for Repligen and 7 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.88 beat Repligen's score of 0.49 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bio-Rad Laboratories	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Repligen beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Techne?

Bio-Rad Laboratories (NYSE:BIO) and Bio-Techne (NASDAQ:TECH) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Bio-Techne has a net margin of 9.05% compared to Bio-Rad Laboratories' net margin of 6.52%. Bio-Techne's return on equity of 13.57% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
Bio-Techne	9.05%	13.57%	10.66%

Bio-Rad Laboratories has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	2.98	$759.90M	$6.07	47.36
Bio-Techne	$1.22B	6.00	$73.40M	$0.69	67.68

Bio-Rad Laboratories currently has a consensus target price of $303.33, indicating a potential upside of 5.51%. Bio-Techne has a consensus target price of $65.92, indicating a potential upside of 41.16%. Given Bio-Techne's stronger consensus rating and higher probable upside, analysts clearly believe Bio-Techne is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Bio-Rad Laboratories had 3 more articles in the media than Bio-Techne. MarketBeat recorded 7 mentions for Bio-Rad Laboratories and 4 mentions for Bio-Techne. Bio-Rad Laboratories' average media sentiment score of 0.88 beat Bio-Techne's score of 0.73 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Techne beats Bio-Rad Laboratories on 11 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Agilent Technologies?

Bio-Rad Laboratories (NYSE:BIO) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Agilent Technologies had 2 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 9 mentions for Agilent Technologies and 7 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.88 beat Agilent Technologies' score of 0.25 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bio-Rad Laboratories presently has a consensus target price of $303.33, indicating a potential upside of 5.51%. Agilent Technologies has a consensus target price of $163.71, indicating a potential upside of 44.07%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Agilent Technologies has a net margin of 18.26% compared to Bio-Rad Laboratories' net margin of 6.52%. Agilent Technologies' return on equity of 24.49% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
Agilent Technologies	18.26%	24.49%	12.83%

65.2% of Bio-Rad Laboratories shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Agilent Technologies has higher revenue and earnings than Bio-Rad Laboratories. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	2.98	$759.90M	$6.07	47.36
Agilent Technologies	$6.95B	4.62	$1.30B	$4.53	25.09

Bio-Rad Laboratories has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Summary

Agilent Technologies beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

Bio-Rad Laboratories (NYSE:BIO) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Bio-Rad Laboratories currently has a consensus price target of $303.33, suggesting a potential upside of 5.51%. AMN Healthcare Services has a consensus price target of $25.29, suggesting a potential downside of 5.91%. Given Bio-Rad Laboratories' higher possible upside, equities analysts clearly believe Bio-Rad Laboratories is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AMN Healthcare Services	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.44

Bio-Rad Laboratories has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	2.98	$759.90M	$6.07	47.36
AMN Healthcare Services	$2.73B	0.38	-$95.70M	-$0.87	N/A

Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

In the previous week, Bio-Rad Laboratories and Bio-Rad Laboratories both had 7 articles in the media. Bio-Rad Laboratories' average media sentiment score of 0.88 beat AMN Healthcare Services' score of 0.23 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bio-Rad Laboratories has a net margin of 6.52% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
AMN Healthcare Services	-0.95%	18.01%	5.19%

Summary

Bio-Rad Laboratories beats AMN Healthcare Services on 9 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Bio-Rad Laboratories (NYSE:BIO.B) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

In the previous week, Bio-Rad Laboratories had 7 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 7 mentions for Bio-Rad Laboratories and 0 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.88 beat Bio-Rad Laboratories' score of 0.00 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.

Company	Overall Sentiment
Bio-Rad Laboratories	Positive
Bio-Rad Laboratories	Neutral

Bio-Rad Laboratories currently has a consensus price target of $303.33, indicating a potential upside of 5.51%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bio-Rad Laboratories has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
Bio-Rad Laboratories	6.52%	3.56%	2.49%

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	2.98	$759.90M	$6.07	47.36
Bio-Rad Laboratories	$2.59B	2.76	$759.90M	$6.07	44.06

Summary

Bio-Rad Laboratories beats Bio-Rad Laboratories on 10 of the 11 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIO vs. The Competition

Export

Metric	Bio-Rad Laboratories	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$7.52B	$8.47B	$6.30B	$22.72B
Dividend Yield	N/A	2.52%	2.80%	4.13%
P/E Ratio	47.36	16.21	20.82	29.94
Price / Sales	2.98	8.35	523.01	91.59
Price / Cash	28.04	16.94	43.18	24.44
Price / Book	1.12	3.98	9.86	4.67
Net Income	$759.90M	$224.05M	$3.55B	$1.07B
7 Day Performance	16.92%	0.70%	-0.79%	-0.38%
1 Month Performance	-6.06%	0.48%	-1.16%	-0.30%
1 Year Performance	25.85%	1.08%	33.71%	26.83%

Bio-Rad Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIO Bio-Rad Laboratories	1.5561 of 5 stars	$287.49 +2.3%	$303.33 +5.5%	+16.5%	$7.52B	$2.58B	47.36	7,450	Positive News Gap Up
RGEN Repligen	3.9501 of 5 stars	$115.91 -6.1%	$169.62 +46.3%	-12.4%	$6.96B	$738.26M	128.79	2,000
TECH Bio-Techne	4.0049 of 5 stars	$47.42 -1.9%	$66.77 +40.8%	-5.7%	$7.57B	$1.22B	68.73	3,100	Ex-Dividend Gap Up
A Agilent Technologies	4.8688 of 5 stars	$111.73 -3.4%	$163.71 +46.5%	+0.1%	$32.67B	$6.95B	24.66	18,100	Upcoming Earnings
AMN AMN Healthcare Services	1.7072 of 5 stars	$30.43 +5.0%	$23.50 -22.8%	+17.3%	$1.12B	$2.73B	N/A	2,664	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BIO) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Rad Laboratories (BIO) Competitors

BIO vs. RGEN, TECH, A, AMN, and BIO.B

How does Bio-Rad Laboratories compare to Repligen?

Summary

How does Bio-Rad Laboratories compare to Bio-Techne?

Summary

How does Bio-Rad Laboratories compare to Agilent Technologies?

Summary

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

Summary

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Rad Laboratories (BIO) Competitors

BIO vs. RGEN, TECH, A, AMN, and BIO.B

How does Bio-Rad Laboratories compare to Repligen?

Is RGEN or BIO more profitable?

Do institutionals & insiders hold more shares of RGEN or BIO?

Which has more volatility & risk, RGEN or BIO?

Do analysts prefer RGEN or BIO?

Which has stronger earnings and valuation, RGEN or BIO?

Does the media refer more to RGEN or BIO?

Summary

How does Bio-Rad Laboratories compare to Bio-Techne?

Is BIO or TECH more profitable?

Which has more volatility & risk, BIO or TECH?

Which has preferable earnings & valuation, BIO or TECH?

Do analysts rate BIO or TECH?

Do institutionals and insiders have more ownership in BIO or TECH?

Does the media prefer BIO or TECH?

Summary

How does Bio-Rad Laboratories compare to Agilent Technologies?

Does the media prefer BIO or A?

Do analysts prefer BIO or A?

Is BIO or A more profitable?

Do institutionals & insiders have more ownership in BIO or A?

Which has preferable valuation and earnings, BIO or A?

Which has more risk & volatility, BIO or A?

Summary

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

Do analysts recommend BIO or AMN?

Which has better valuation and earnings, BIO or AMN?

Which has more risk & volatility, BIO or AMN?

Does the media favor BIO or AMN?

Do insiders & institutionals have more ownership in BIO or AMN?

Is BIO or AMN more profitable?

Summary

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Does the media prefer BIO or BIO.B?

Do analysts rate BIO or BIO.B?

Which has more risk & volatility, BIO or BIO.B?

Is BIO or BIO.B more profitable?

Do insiders & institutionals have more ownership in BIO or BIO.B?

Which has higher earnings and valuation, BIO or BIO.B?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools